Clear Street’s Theriva Biologics TOVX Stock Holding History

Clear Street’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100	Closed	-$41	–	1002
2025 Q3	$41	Hold	100	–	–	﹤0.01%	823
2025 Q2	$43	Buy	+100	New	+$81	﹤0.01%	653

Other funds holding TOVX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Clear Street's TOVX Position: Q4 2025 in Review

Clear Street sold out of Theriva Biologics (TOVX) in Q4 2025, closing a stake of 100 shares — an estimated $41 sold.

Clear Street first reported a position in TOVX in Q2 2025 and held it in 2 quarters. The position peaked at $43 in Q2 2025. 21 funds tracked by Wall St. Rank hold TOVX as of Q4 2025.

Clear Street reported no remaining Theriva Biologics position as of Q4 2025 after selling out during the quarter.
Clear Street sold 100 Theriva Biologics shares in Q4 2025, an estimated $41.
Clear Street first reported a position in Theriva Biologics in Q2 2025 and held it in 2 quarters.
Clear Street's Theriva Biologics position peaked at $43 in Q2 2025.
21 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2025.

Based on Clear Street's 13F filing for Q4 2025, filed 13 Feb 2026.